Getein Biotech Hits Day High with Strong 10.02% Intraday Surge

Getein Biotech, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a significant uptick in its stock performance today, gaining 10.02% as of March 17, 2026. The stock reached an intraday high of CNY 9.44, marking a notable achievement in a challenging market environment. In comparison to the broader market, Getein Biotech's performance stands out, particularly against the China Shanghai Composite, which has declined by 0.85% on the same day. Over the past week, the stock has shown a robust increase of 11.58%, while its monthly performance reflects an 8.63% rise. However, it is important to note that the company has faced long-term challenges, with a three-year performance decline of 30.13% and a five-year drop of 45.85%. Despite these hurdles, Getein Biotech maintains a dividend yield of 2.07% and a price-to-book ratio of 1.64, indicating a potentially attractive valuation. The company's market capitalization stands at CNY 4,407 million, reflecting its position within the small-cap segment of the market.